ERBB2 and breast cancer: In an independent study using 111 BC samples, Bellmunt et al. demonstrated that Her2/neu over-expression was observed in 22 % of the analyzed cohort [16], and could reached in some cases a record ratio of 74 %, as reported elsewhere [17].